Home
Post
Share
@CovidAnalysis
Meta AnalysisMeta
Atilotrelvir was adopted
in 1 country.
Submit updates/corrections .
Summary.
Jan 25 |
Atilotrelvir for COVID-19: real-time meta analysis of 1 study | |
| Significantly lower risk is seen for recovery and viral clearance. Meta analysis using the most serious outcome reported shows 13% [1‑23%] lower risk. Currently there is very limited data, with only one study to date. No treatm.. | ||
May 31 |
et al., eClinicalMedicine, doi:10.1016/j.eclinm.2024.102582 | Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial |
| 13% faster recovery (p=0.03) and 25% faster viral clearance (p<0.0001). RCT 1,213 outpatients with mild-to-moderate COVID-19 in China showing a shorter time to sustained recovery and faster viral clearance with GST-HG171 (atilotrelvir) plus ritonavir. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.